| Dr Brett Barry Bender, DO | |
|
5701 Bow Pointe Dr Ste 215, Clarkston, MI 48346-5400 | |
| (248) 620-3376 | |
| (248) 620-3379 |
| Full Name | Dr Brett Barry Bender |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 22 Years |
| Location | 5701 Bow Pointe Dr Ste 215, Clarkston, Michigan |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285752998 | NPI | - | NPPES |
| 0756319375 | Other | MI | BLUE CROSS BLUE SHIELD |
| 0756319375 | Other | MI | BLUE CARE NETWORK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 5101016359 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Joseph Mercy Hospital | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Midwest Center For Dermatology And Pathology Pllc | 0446330492 | 43 |
News Archive
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC's proprietary CAP GT technology.
NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.
A UCSF analysis of published studies on the relationship between Alzheimer's disease and smoking indicates that smoking cigarettes is a significant risk factor for the disease. After controlling for study design, quality of the journals, time of publication, and tobacco industry affiliation of the authors, the UCSF research team also found an association between tobacco industry affiliation and the conclusions of individual studies.
A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.
› Verified 8 days ago
| Entity Name | Midwest Center For Dermatology & Pathology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003095084 PECOS PAC ID: 0446330492 Enrollment ID: O20080103000679 |
News Archive
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC's proprietary CAP GT technology.
NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.
A UCSF analysis of published studies on the relationship between Alzheimer's disease and smoking indicates that smoking cigarettes is a significant risk factor for the disease. After controlling for study design, quality of the journals, time of publication, and tobacco industry affiliation of the authors, the UCSF research team also found an association between tobacco industry affiliation and the conclusions of individual studies.
A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brett Barry Bender, DO 5701 Bow Pointe Dr Ste 215, Clarkston, MI 48346-5400 Ph: (248) 620-3376 | Dr Brett Barry Bender, DO 5701 Bow Pointe Dr Ste 215, Clarkston, MI 48346-5400 Ph: (248) 620-3376 |
News Archive
CEVEC Pharmaceuticals GmbH, the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced a collaboration agreement with Généthon (Evry, France) for the development and exploitation of lentivirus packaging cell lines based on CEVEC's proprietary CAP GT technology.
NovaDel Pharma Inc., a specialty pharmaceutical company that develops oral spray formulations of marketed pharmaceutical products, today announced its entry into an exclusive license and distribution agreement with Rechon Life Science AB to manufacture and commercialize Zolpimist® outside the United States and Canada. Zolpimist is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.
A UCSF analysis of published studies on the relationship between Alzheimer's disease and smoking indicates that smoking cigarettes is a significant risk factor for the disease. After controlling for study design, quality of the journals, time of publication, and tobacco industry affiliation of the authors, the UCSF research team also found an association between tobacco industry affiliation and the conclusions of individual studies.
A newly developed antifungal, isavuconazole, is as effective as an existing drug, voriconazole, against invasive mold disease in cancer patients with less adverse effects, according to phase 3 clinical data presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting of the American Society for Microbiology.
› Verified 8 days ago
Susan Hanson Klemmer, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 6080 Dixie Hwy, Suite B, Clarkston, MI 48346 Phone: 248-623-9700 Fax: 248-623-8996 | |
Brian A Kopitzki, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5701 Bow Pointe Dr Ste 215, Clarkston, MI 48346 Phone: 248-620-3376 Fax: 248-620-3376 | |
Jennifer Trepte Caudill, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5885 S. Main St., Suite 1, Clarkston, MI 48346 Phone: 248-623-9700 Fax: 248-623-8996 | |
Dr. Wendy L Mcfalda, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5701 Bow Pointe Dr, Suite 215, Clarkston, MI 48346 Phone: 248-620-3376 Fax: 248-620-3379 | |
Dr. Richard Saul Schwartz, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 6770 Dixie Hwy, Suite 304, Clarkston, MI 48346 Phone: 248-625-1123 Fax: 248-625-7044 |